Summary
October 2007, Vol. 11, No. 10, Pages 1287-1298 , DOI 10.1517/14728222.11.10.1287

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

Paraic A Kenny
Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS977-225A, University of California, Berkeley, CA 94720, USA



TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors.

Full Text | PDF (2385 KB) | PDF Plus (2674 KB)

Forward Links to Citing Articles

Mark Katakowski, Feng Jiang, XuGuang Zheng, Jorge A. Gutierrez, Alexandra Szalad, Michael Chopp. (2009) Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Science
Online publication date: 1-Jul-2009.
CrossRef
Brian W. Booth, Gilbert H. Smith. (2007) Roles of transforming growth factor-α in mammary development and disease. Growth Factors 25:4, 227-235
Online publication date: 1-Jan-2007.
Summary | Full Text | PDF (199 KB) | PDF Plus (200 KB) 
 

Prev. Article | Next Article
View/Print PDF (2385 KB)
View PDF Plus (2674 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Author:
Paraic A Kenny
Keywords:
ADAM17
cancer
EGFR
metalloprotease inhibitor
sheddase